Chat with us
Research Assistance
Online
  • Please enter your first name.

U.S. Gene Therapy Market Size & Outlook, 2023-2030

The gene therapy market in the United States is expected to reach a projected revenue of US$ 18,484.0 million by 2030. A compound annual growth rate of 18.8% is expected of the United States gene therapy market from 2024 to 2030.

  • Biotechnology
    • Gene Expression & Gene Therapy
      • Gene Therapy Market Outlook
Revenue, 2023 (US$M)
$5,533.7
Forecast, 2030 (US$M)
$18,484.0
CAGR, 2024 - 2030
18.8%
Report Coverage
U.S.

U.S. Gene Therapy Market, 2018-2030 (US$M)

U.S. Gene Therapy Market, 2018-2030 (US$M)

This page contains premium content. Request sample data or start your free trial to explore Horizon.

  • ✔ Access to global market statistics
  • ✔ Access to company profiles
  • ✔ Free use-cases & research insights

No credit card required*

U.S. gene therapy market highlights

  • The U.S. gene therapy market generated a revenue of USD 5,533.7 million in 2023 and is expected to reach USD 18,484.0 million by 2030.
  • The U.S. market is expected to grow at a CAGR of 18.8% from 2024 to 2030.
  • In terms of segment, other vector type was the largest revenue generating vector type in 2023.
  • AAV is the most lucrative vector type segment registering the fastest growth during the forecast period.

Gene therapy market data book summary

Market revenue in 2023USD 5,533.7 million
Market revenue in 2030USD 18,484.0 million
Growth rate18.8% (CAGR from 2024 to 2030)
Largest segmentOther vector type
Fastest growing segmentAAV
Historical data2018 - 2022
Base year2023
Forecast period2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationLentivirus, AAV, RetroVirus & gamma RetroVirus, Modified Herpes Simplex Virus, Other Vector Type
Key market players worldwideRegenxbio Inc, Oxford Biomedical Research, Bristol-Myers Squibb Co, Sanofi SA, Ultragenyx Pharmaceutical Inc, Roche Holding AG ADR, Bluebird bio Inc, Novartis AG ADR, UniQure NV, Cellectis SA, Sangamo Therapeutics Inc, Benitec Biopharma Inc, SiBiono GeneTech, Transgene SA, Gensight Biologics SA, Astellas Pharma Inc

Other key industry trends

  • In terms of revenue, U.S. accounted for 64.5% of the global gene therapy market in 2023.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In North America, U.S. gene therapy market is projected to lead the regional market in terms of revenue in 2030.
  • U.S. is the fastest growing regional market in North America and is projected to reach USD 18,484.0 million by 2030.

The U.S. is the largest market for clinical trials related to gene therapy, as around 50% of all clinical trials in the world are conducted in the country. As of March 2023, more than 2,500 clinical studies are under investigation in the U.S. alone. 

A large number of gene therapy trials focus on finding feasible treatment options for cancer, closely followed by genetic diseases and neurological disorders. 

The local presence of several large companies and small startups—working on the development of gene therapies—and partnerships & mergers between them are anticipated to boost the market.

No credit card required*

Publish Date: Mar 17, 2025

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Three ways to get this data

Subscribe to the databook, customize it, or ask a question.

Horizon Databook

Unlock every chart on this page and get dashboard access

  • Statistics1.2M+ across all markets
  • Databooks30K+ global, 120K+ country
  • Companies200K+ profiles
  • ExportPDF, Dashboard, XLS & PNG, licensed to cite

Ask Prism AI

A cited answer in seconds

  • Corpus30,000 studies, 1.2M points
  • ScopeAll markets, not just this
  • CitationTraced to report & table
  • HonestySays "not covered" if so
  • SpeedSeconds, not days
ISO 9001 & 27001 certifiedESOMAR memberNot sure which fits? Call +1-415-854-0727

Gene Therapy Market Companies

NameProfile# EmployeesHQWebsite
Novartis AG ADRView profile 76,057Lichtstrasse 35, Basel, Switzerland, 4056www.novartis.com
Roche Holding AG ADRView profile 103,605Grenzacherstrasse 124, Basel, Switzerland, 4070www.roche.com
Sanofi SAView profile 87,99446, avenue de la Grande Armée, Paris, France, 75017www.sanofi.com
Bristol-Myers Squibb CoView profile 34,100Route 206 and Province Line Road, Princeton, New Jersey, NJ, United States, 08543www.bms.com
UniQure NVView profile 480Paasheuvelweg 25, Amsterdam, NH, Netherlands, 1105 BPwww.uniqure.com
SiBiono GeneTechView profile 1001-5000Shenzhen, Guangdong, China, Asiawww.sibiono.com
Cellectis SAView profile 2168, rue de la Croix Jarry, Paris, France, 75013www.cellectis.com
Astellas Pharma IncView profile 14,4842-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, Japan, 103-8411www.astellas.com
Bluebird bio IncView profile 323455 Grand Union Boulevard, Somerville, MA, United States, 02145www.bluebirdbio.com
Sangamo Therapeutics IncView profile 405501 Canal Boulevard, Richmond, CA, United States, 94804www.sangamo.com

U.S. Gene Therapy Market Outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Gene Therapy Market Outlook will help companies and investors design strategic landscapes.


Other Vector Type was the largest segment with a revenue share of 47.62% in 2023.

Horizon Databook has segmented the U.S. gene therapy market based on lentivirus, aav, retrovirus & gamma retrovirus, modified herpes simplex virus, other vector type covering the revenue growth of each sub-segment from 2018 to 2030.




The U.S. is the largest market for clinical trials related to gene therapy, as around 50% of all clinical trials in the world are conducted in the country. As of March 2023, more than 2,500 clinical studies are under investigation in the U.S. alone. 

A large number of gene therapy trials focus on finding feasible treatment options for cancer, closely followed by genetic diseases and neurological disorders. 

The local presence of several large companies and small startups—working on the development of gene therapies—and partnerships & mergers between them are anticipated to boost the market.

  • U.S. Gene Therapy Market Vector Type Outlook (Revenue, USD Million , 2018-2030)
    • Lentivirus
    • AAV
    • RetroVirus & gamma RetroVirus
    • Modified Herpes Simplex Virus
    • Adenovirus
    • Non-viral Plasmid Vector
    • Other Vector Type
  • U.S. Gene Therapy Market Indication Outlook (Revenue, USD Million , 2018-2030)
    • Acute Lymphoblastic Leukemia (ALL)
    • Inherited Retinal Disease
    • Large B-cell Lymphoma
    • ADA-SCID
    • Melanoma (lesions)
    • Beta-Thalassemia Major/SCD
    • Head & Neck Squamous Cell Carcinoma
    • Peripheral arterial disease
    • Spinal Muscular Atrophy (SMA) 
    • Others

Reasons to subscribe to Gene Therapy Market Outlook databook

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Gene Therapy Market Outlook databook

  • Our clientele includes a mix of Gene Therapy Market Outlook companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the U.S. Gene Therapy Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into U.S. Gene Therapy Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.

U.S. Gene Therapy Market, 2018-2030 (US$M)

No Access Stack Chart

U.S. gene therapy market statistics, by vector type, 2018-2030 (US$M)

No Access Pie Chart

U.S. gene therapy market statistics, by vector type, 2018-2030 (USD Million)

No Access

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more